Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease

Abstract

Background Statins are commonly used in the secondary prevention of coronary artery disease. Studies have shown that the rate of statin use is low among patients with coronary artery disease. In this study, we aimed to investigate the reasons for poor patient compliance with statin treatment. Methods A total of 504 patients diagnosed with coronary heart disease were included in the study. Patients were asked 5 questions to assess their level of knowledge about statin therapy. Results Among the patients not using statins, 42% stated they did not take the medication because their cholesterol was not high or they did not know they should renew their prescription when they ran out and 35% because they were influenced by news reports in the media suggesting that cholesterol-lowering drugs were harmful. When patients who were aware of the pleiotropic/cardioprotective effects of statins were compared with patients who were not, the more knowledgeable patients had lower noncompliance rate and mean LDL-C level and a higher rate of LDL-C level optimization. Conclusion We found that patients who are aware of the pleiotropic effects of statins were more compliant with treatment. We believe that spending more time explaining and emphasizing the mechanisms of action, reason for prescribing, and necessary treatment duration of drugs that patients must use will result in greater compliance and improve patient care. In this way, patients may be less influenced by misinformation presented by the media.

Kayseri Şehir Hastanesi Kardiyoloji Kliniğinde Koroner Arter Hastalığı Olan Hastalarda Lipid Düşürücü İlaç Kullanımına Uyum ve LDL-Kolesterol Hedefine Ulaşma Düzeyleri

“…18 Bu çalışmaya benzer şekilde Özkan ve ark.nın yaptığı çalışmada, hastaların doktor tarafından lipid düşürücü ilaçlar konusunda bilgilendirilmesi, tedaviye olan uyumu artırmakta, gerek medya gerekse çevresel koşullar nedeniyle yanlış yönlendirmelerin önüne geçmektedir. 19 Çalışmamız sonuçlarına göre düşük olan ilaç kullanım düzeyleri ve lipid düzeyi takipleri, hasta ve hasta yakınlarına verilecek eğitim ile artırılabilir. Bu konu hakkında ülke genelinde yapılacak kamu bilgilendirmeleri toplum üzerinde hiperlipidemi konusunda bir farkındalık sağlayacaktır.…”

“…Kayseri çevresinde yapılan başka bir çalışmada hasta ve hasta yakınlarını kardiyovaskuler risk faktörleri, önlenmesi ve yönetilmesi ile ilgili bilgi düzeyi arttıkça sağlıklı yaşam biçimi davranışı belirleme eğilimleri olduğu belirtilmiştir 18. Bu çalışmaya benzer şekilde Özkan ve ark.nın yaptığı çalışmada, hastaların doktor tarafından lipid düşürücü ilaçlar konusunda bilgilendirilmesi, tedaviye olan uyumu artırmakta, gerek medya gerekse çevresel koşullar nedeniyle yanlış yönlendirmelerin önüne geçmektedir 19. Çalışmamız sonuçlarına göre düşük olan ilaç kullanım düzeyleri ve lipid düzeyi takipleri, hasta ve hasta yakınlarına verilecek eğitim ile artırılabilir.…”

Early effects of atorvastatin on Vitamin D and parathyroid hormone serum levels following acute myocardial infarction

“…[30] According to the current available guidelines, starting atorvastatin is one of the earliest recommended therapies for acute MI, owing to its pleiotropic effects. [3132] Long-term effects of atorvastatin administration on Vitamin D level have been defined in previous studies. [79112122] The mechanism by which atorvastatin increases Vitamin D levels is attributed to inhibition of 3-hydroxy-3 methylglutaryl coenzyme A reductase.…”

Omega-3 PUFAs’ efficacy in the therapy of coronary artery disease combined with anxiety or depression: a meta-analysis

“…Coronary heart disease (CHD) is caused by the narrowing or occlusion of coronary arteries, resulting in ischemia, hypoxia, or necrosis of the myocardium. It has the highest death rate ( 1 ), and anxiety and depression can make it more likely that bad prognostic events will happen. A relevant summary analysis indicates that anxiety and depression increase the incidence of adverse cardiac outcomes in acute myocardial infarction prognosis by 36% ( 2 ).…”